SunBio, Inc. Logo

SunBio, Inc.

Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.

067370 | KO

Overview

Corporate Details

ISIN(s):
KR7067370007
LEI:
Country:
South Korea
Address:
인천광역시 남동구 은봉로 129 -, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SunBio, Inc. is a biotechnology company that develops, produces, and commercializes biosimilars, biopharmaceuticals, and medical devices. The company's core research and development activities are based on its proprietary PEGylation technology, a platform used to enhance the efficacy and duration of therapeutic drugs. Key products in its pipeline include an artificial blood substitute and MucoPEG, a treatment for xerostomia (dry mouth).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 61.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-07 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.7 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.5 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-24 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.8 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 353.1 KB
2025-03-21 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 94.4 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 18.8 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2024-12-11 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all SunBio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SunBio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SunBio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.